Sartorius/€SRT3

1D1W1MYTD1Y5YMAX

About Sartorius

Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.
Ticker
€SRT3
Sector
Health
Primary listing
XETRA
Employees
14,279
Headquarters
Göttingen, Germany
Website
www.sartorius.com

Sartorius Metrics

BasicAdvanced
€15B
-
-
1.47
€0.74
0.30%

What the Analysts think about Sartorius

Analyst ratings (Buy, Hold, Sell) for Sartorius stock.
Analyst projections of the future price of Sartorius stock.

Bulls say / Bears say

Recurring consumables remain the main growth engine, with Bioprocess Solutions delivering 8.3% operational growth in constant currencies in the first half and its EBITDA margin rising to 32.3%. This supports Sartorius’s 2026 guidance and shows that its installed base generates resilient repeat revenue. (Sartorius)
The delayed equipment cycle is beginning to turn, while Asia-Pacific grew 12.1% in constant currencies and China continued to recover. A broader improvement in equipment and laboratory instruments could add growth beyond the current consumables-led recovery. (Sartorius, Investing.com)
Management’s medium-term ambition is for 8% to 11% annual organic sales growth from 2027, with EBITDA margins expanding by 50 to 75 basis points a year. If Sartorius outgrows its bioprocessing and laboratory markets as planned, operating leverage could make earnings grow faster than sales. (Webdisclosure)
The US tariff settlement is directly reducing reported growth: Sartorius expects customer compensation to cut 2026 revenue by up to €40 million, pushing Group and Bioprocess Solutions growth towards the lower half of their guidance ranges. Further changes in US trade policy remain an additional source of uncertainty. (Sartorius, Endpoints News)
Advanced-therapy demand is still lumpy, with two major customers delaying orders and most of the related revenue now expected in 2027. That weakens near-term visibility and shows that the recovery is not yet broad across all biopharma modalities. (Ticker Report, American Market News)
The balance sheet remains a constraint while Sartorius is still investing heavily: management expects year-end net debt to remain slightly above three times underlying EBITDA and capital expenditure to stay around 12.5% of sales. High leverage and ongoing investment leave less room if the equipment recovery or margins disappoint. (Sartorius, ROIC AI)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.

Sartorius Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Sartorius Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Sartorius

AllEURGBPUSD
Funds
Fund name
Fund size
€SRT3 weighting
iShares TecDAX€EXS2
€645M4.82%
iShares MDAX€EXS3
€1.5B4.03%
iShares MDAX€EXID
€34M3.76%
iShares EURO STOXX Mid€DJMC
€572M0.77%
iShares EURO STOXX Mid Cap£DJMC
£491M0.77%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.